Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your digital twin could help prevent another stroke

NCT ID NCT06714097

Recruiting now Knowledge-focused Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tests a smartphone app that creates a 'digital twin' of the patient to help manage health after a stroke, moyamoya disease, or cerebral amyloid angiopathy. Twenty adults will either use the app plus standard care, or standard care alone. The goal is to see if patients find the app helpful and easy to use, not to measure medical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
STRATIF-AI digital twin app (software)
What this could lead to
If it works, this could point toward a better way to help patients manage their health after a stroke or similar condition.
What could go wrong
This is a very small, early study with only 20 people. It is testing if the app is usable, not if it prevents strokes. The app may not improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CEREBRAL AMYLOID ANGIOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral amyloid angiopathy Moyamoya disease stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CEREBRAL AMYLOID ANGIOPATHY MOYAMOYA DISEASE STROKE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, Michigan, 20133, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.